Research Article
BibTex RIS Cite

Papiller Tiroid Kanserli Hastalarda Preoperatif Santral Lenf Nodu Metastazının Öngörücüsü Olarak Glikoz-Lenfosit Oranı

Year 2022, , 534 - 539, 30.12.2022
https://doi.org/10.18663/tjcl.1148122

Abstract

Amaç
Papillertiroid kanserinde santral lenf nodlarının metastazının cerrahi öncesi saptanması zordur. Papiller tiroid kanserinin tedavisinde santral lenf nodu diseksiyonunun rolü belirsizliğini koruyor. Bu çalışma, papiller tiroid kanserli hastalarda preoperatif santral lenf nodu metastazı oluşumunu öngörmek için hazır preoperatif klinik özelliklere dayalı bir nomogram oluşturmayı amaçladı
Gereç ve Yöntemler
2013-2022 tarihleri arasında bilateral total tiroidektomi yapılmış papillertiroid karsinomu tanılı hastalar tarandı ve 314 hasta çalışmaya dahil edildi. Hastaların demografik verileri, operasyon süresi, TSH, T3, T4 düzeyleri, glukoz/lenfosit oranları (GLR), patoloji raporlarındaki lenfovasküler invazyon, kapsül invazyonu ve boyun metastazı durumu retrospektif olarak taranarak not edildi. Tüm istatistiksel analizler için IBM SPSS 26.0 kullanılarak değerlendirildi. p<0.05 değerler anlamlı olarak kabul edildi. Parametrelerin prediktif değerleri için ROC analizi yapılarak hesaplandı.
Bulgular
Lenfovakülerinvazyonda GLR değeri hesaplandığında invazyon olmayan grupta 61,21±39,77 invazyon olan grupta ise 103,2±48 bulundu, iki grup arasında istatistiki anlamlı farklılık gözlendi (p<0,001). Boyun metastazında GLR değeri non-metastatik grupta 66,12±43,6 , metastatik olan grupta ise anlamlı yüksek olacak şekilde 77,3±35,32 bulundu (p<0,041) .Lenfovasküler invazyon ayrımı için en uygun GLR cut-off değeri %73,2 sensitivite, %82,4 spesifite ve %95,3 negatif prediktif değer ile 74,773 olarak bulunmuştur (p<0,001). Boyun metastazı ayrımı için en uygun GLR cut-off değeri %75 sensitivite, %63,8 spesifite ve %97,9 negatif prediktif değer ile 62,382 olarak bulunmuştur (p=0,003).
Sonuçlar
Papiller tiroid kanserli hastalarda, yüksek preoperatif glukoz/lenfosit oranı, lenfovasküler invazyon ve santral lenf nodu metastazının bağımsız bir öngördürücüsüydü. Bu şekilde oluşturulan nomogram, bu hastalarda preoperatif merkezi lenf nodu metastazını daha iyi tahmin edebilir.

References

  • 1- Siegel RL, Miller KD,Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians, 2019; 69(1): 7-34.
  • 2- Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in the cancer incidence and mortality in the United States, 1974-2013. Jama, 2017;17(13): 1338-48.
  • 3- Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. Jama; 2006; 295(18): 2164-67.
  • 4- Hay ID. Papillary thyroid carcinoma. Endocrinology and metabolism clinics of North America 1990; 19(3): 545-76.
  • 5- Leboulleux S, Rubino C, Baudin E et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. The Journal of Clinical Endocrinology & Metabolism, 2005; 90(10); 5723-29.
  • 6- Wang TS, Sosa JA. Thyroid surgery for differentiated thyroid cancer—recent advances and future directions. Nature Reviews Endocrinology 2018;14(11): 670-83.
  • 7- Bilimoria KY,Bentrem DJ, KoCY et al. Extent of surgery affects survival for papillary thyroid cancer. Annals of surgery 2007;246(3): 375.
  • 8- Calò PG, Medas F, Conzo G et al. Intraoperative neuromonitoring in thyroid surgery: Is the two-staged thyroidectomy justified? International Journal of Surgery 2017; 41: 13-20.
  • 9- Zhong A, Cheng CS, Kai J, Lu R, Guo, L.Clinical significance of glucose to lymphocyte ratio (GLR) as a prognostic marker for patients with pancreatic cancer. Frontiers in Oncology 2020; 10: 520330.
  • 10- Navarro J, Kang I, Hwang HK, Yoon DS, Lee WJ, Kang CM. Glucose to lymphocyte ratio as a prognostic marker in patients with resected pT2 gallbladder cancer. Journal of Surgical Research, 2019; 240: 17-29.
  • 11- Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?Lancet 2001;357:539–45.
  • 12- Jayatilleke KM, Hulett MD. Heparanase and the hallmarks of cancer. J Transl Med. 2020;18(1): 453.
  • 13- Kwon J, Bakhoum SF. The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer. Cancer Discov. 2020;10(1):26-39.
  • 14- Mantovani A. Cancer: inflammation by remote control. Nature. 2005;435:752–753
  • 15- Goeppert B, Frauenschuh L, Zucknick M et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. British journal of cancer 2013;109(10): 2665-74.
  • 16- Pacifico F, Leonardi A. Role of NF-κB in thyroid cancer. Molecular and cellular endocrinology 2010; 321(1): 29-35.
  • 17- Han JM, Kim TY, Jeon MJ et al. Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population. Eur J Endocrinol 2013; 168(6): 879-86.
  • 18- Ulmer H,Borena W, Rapp K et al. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. British Journal of Cancer 2009; 101(7): 1202-06.
Year 2022, , 534 - 539, 30.12.2022
https://doi.org/10.18663/tjcl.1148122

Abstract

References

  • 1- Siegel RL, Miller KD,Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians, 2019; 69(1): 7-34.
  • 2- Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in the cancer incidence and mortality in the United States, 1974-2013. Jama, 2017;17(13): 1338-48.
  • 3- Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. Jama; 2006; 295(18): 2164-67.
  • 4- Hay ID. Papillary thyroid carcinoma. Endocrinology and metabolism clinics of North America 1990; 19(3): 545-76.
  • 5- Leboulleux S, Rubino C, Baudin E et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. The Journal of Clinical Endocrinology & Metabolism, 2005; 90(10); 5723-29.
  • 6- Wang TS, Sosa JA. Thyroid surgery for differentiated thyroid cancer—recent advances and future directions. Nature Reviews Endocrinology 2018;14(11): 670-83.
  • 7- Bilimoria KY,Bentrem DJ, KoCY et al. Extent of surgery affects survival for papillary thyroid cancer. Annals of surgery 2007;246(3): 375.
  • 8- Calò PG, Medas F, Conzo G et al. Intraoperative neuromonitoring in thyroid surgery: Is the two-staged thyroidectomy justified? International Journal of Surgery 2017; 41: 13-20.
  • 9- Zhong A, Cheng CS, Kai J, Lu R, Guo, L.Clinical significance of glucose to lymphocyte ratio (GLR) as a prognostic marker for patients with pancreatic cancer. Frontiers in Oncology 2020; 10: 520330.
  • 10- Navarro J, Kang I, Hwang HK, Yoon DS, Lee WJ, Kang CM. Glucose to lymphocyte ratio as a prognostic marker in patients with resected pT2 gallbladder cancer. Journal of Surgical Research, 2019; 240: 17-29.
  • 11- Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?Lancet 2001;357:539–45.
  • 12- Jayatilleke KM, Hulett MD. Heparanase and the hallmarks of cancer. J Transl Med. 2020;18(1): 453.
  • 13- Kwon J, Bakhoum SF. The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer. Cancer Discov. 2020;10(1):26-39.
  • 14- Mantovani A. Cancer: inflammation by remote control. Nature. 2005;435:752–753
  • 15- Goeppert B, Frauenschuh L, Zucknick M et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. British journal of cancer 2013;109(10): 2665-74.
  • 16- Pacifico F, Leonardi A. Role of NF-κB in thyroid cancer. Molecular and cellular endocrinology 2010; 321(1): 29-35.
  • 17- Han JM, Kim TY, Jeon MJ et al. Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population. Eur J Endocrinol 2013; 168(6): 879-86.
  • 18- Ulmer H,Borena W, Rapp K et al. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. British Journal of Cancer 2009; 101(7): 1202-06.
There are 18 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Orıgınal Artıcle
Authors

Ertugrul Gazi Alkurt

Semin Turhan 0000-0002-1014-1179

Fatih Şahin 0000-0002-6505-5884

Mehmet Berksun Tutan 0000-0003-1834-7355

Publication Date December 30, 2022
Published in Issue Year 2022

Cite

APA Alkurt, E. G., Turhan, S., Şahin, F., Tutan, M. B. (2022). Papiller Tiroid Kanserli Hastalarda Preoperatif Santral Lenf Nodu Metastazının Öngörücüsü Olarak Glikoz-Lenfosit Oranı. Turkish Journal of Clinics and Laboratory, 13(4), 534-539. https://doi.org/10.18663/tjcl.1148122
AMA Alkurt EG, Turhan S, Şahin F, Tutan MB. Papiller Tiroid Kanserli Hastalarda Preoperatif Santral Lenf Nodu Metastazının Öngörücüsü Olarak Glikoz-Lenfosit Oranı. TJCL. December 2022;13(4):534-539. doi:10.18663/tjcl.1148122
Chicago Alkurt, Ertugrul Gazi, Semin Turhan, Fatih Şahin, and Mehmet Berksun Tutan. “Papiller Tiroid Kanserli Hastalarda Preoperatif Santral Lenf Nodu Metastazının Öngörücüsü Olarak Glikoz-Lenfosit Oranı”. Turkish Journal of Clinics and Laboratory 13, no. 4 (December 2022): 534-39. https://doi.org/10.18663/tjcl.1148122.
EndNote Alkurt EG, Turhan S, Şahin F, Tutan MB (December 1, 2022) Papiller Tiroid Kanserli Hastalarda Preoperatif Santral Lenf Nodu Metastazının Öngörücüsü Olarak Glikoz-Lenfosit Oranı. Turkish Journal of Clinics and Laboratory 13 4 534–539.
IEEE E. G. Alkurt, S. Turhan, F. Şahin, and M. B. Tutan, “Papiller Tiroid Kanserli Hastalarda Preoperatif Santral Lenf Nodu Metastazının Öngörücüsü Olarak Glikoz-Lenfosit Oranı”, TJCL, vol. 13, no. 4, pp. 534–539, 2022, doi: 10.18663/tjcl.1148122.
ISNAD Alkurt, Ertugrul Gazi et al. “Papiller Tiroid Kanserli Hastalarda Preoperatif Santral Lenf Nodu Metastazının Öngörücüsü Olarak Glikoz-Lenfosit Oranı”. Turkish Journal of Clinics and Laboratory 13/4 (December 2022), 534-539. https://doi.org/10.18663/tjcl.1148122.
JAMA Alkurt EG, Turhan S, Şahin F, Tutan MB. Papiller Tiroid Kanserli Hastalarda Preoperatif Santral Lenf Nodu Metastazının Öngörücüsü Olarak Glikoz-Lenfosit Oranı. TJCL. 2022;13:534–539.
MLA Alkurt, Ertugrul Gazi et al. “Papiller Tiroid Kanserli Hastalarda Preoperatif Santral Lenf Nodu Metastazının Öngörücüsü Olarak Glikoz-Lenfosit Oranı”. Turkish Journal of Clinics and Laboratory, vol. 13, no. 4, 2022, pp. 534-9, doi:10.18663/tjcl.1148122.
Vancouver Alkurt EG, Turhan S, Şahin F, Tutan MB. Papiller Tiroid Kanserli Hastalarda Preoperatif Santral Lenf Nodu Metastazının Öngörücüsü Olarak Glikoz-Lenfosit Oranı. TJCL. 2022;13(4):534-9.


e-ISSN: 2149-8296

The content of this site is intended for health care professionals. All the published articles are distributed under the terms of

Creative Commons Attribution Licence,

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.